![Azithromycin not effective against COVID-19, trial confirms | NIHR Oxford Biomedical Research Centre Azithromycin not effective against COVID-19, trial confirms | NIHR Oxford Biomedical Research Centre](https://oxfordbrc.nihr.ac.uk/wp-content/uploads/2021/04/Azithromycin-credit-Doctor4U.jpg)
Azithromycin not effective against COVID-19, trial confirms | NIHR Oxford Biomedical Research Centre
![Full article: Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations Full article: Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations](https://www.tandfonline.com/cms/asset/67e433f9-51fe-413e-9032-88eb0e867013/dcop_a_23655_f0001_b.jpg)
Full article: Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations
![What is the evidence for using macrolide antibiotics to treat COVID-19? - The Centre for Evidence-Based Medicine What is the evidence for using macrolide antibiotics to treat COVID-19? - The Centre for Evidence-Based Medicine](https://www.cebm.net/wp-content/uploads/2020/04/macrolide.jpg)
What is the evidence for using macrolide antibiotics to treat COVID-19? - The Centre for Evidence-Based Medicine
![Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment - ScienceDirect Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0012369218302459-gr1.jpg)
Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment - ScienceDirect
![Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies - ScienceDirect Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0091674919303884-fx1.jpg)
Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies - ScienceDirect
![Frontiers | Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations Frontiers | Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations](https://www.frontiersin.org/files/Articles/1229463/fmed-10-1229463-HTML-r2/image_m/fmed-10-1229463-g001.jpg)
Frontiers | Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations
Duration of long-term azithromycin courses prescribed by respondents... | Download Scientific Diagram
![Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial - The Lancet Respiratory Medicine Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/f516168b-ca27-473e-b972-7e038d69ea88/gr1.gif)